Simone Seiter
Director/Board Member at GENSIGHT BIOLOGICS S.A.
Profile
Dr. Simone Seiter is a Senior Partner at Simon-Kucher & Partners, Inc., an Independent Director at Gensight Biologics SA and a Head-Clinical & Commercial Advisory Board at Priothera SAS.
He is on the Board of Directors at Gensight Biologics SA. Dr. Seiter was previously employed as a Vice President by IQVIA.
He received his graduate degree from Ruprecht-Karls-Universität Heidelberg, an MBA from the University of Applied Sciences Fh Rendsburg and a doctorate degree from Ruprecht-Karls-Universität Heidelberg.
Simone Seiter active positions
| Companies | Position | Start |
|---|---|---|
| GENSIGHT BIOLOGICS S.A. | Director/Board Member | 2017-04-18 |
Priothera SAS
 Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The private company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020. | Founder | - |
Former positions of Simone Seiter
| Companies | Position | End |
|---|---|---|
| IQVIA | Corporate Officer/Principal | 2018-12-31 |
| Simon-Kucher & Partners, Inc. | Corporate Officer/Principal | - |
Training of Simone Seiter
| Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
| University of Applied Sciences Fh Rendsburg | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| GENSIGHT BIOLOGICS S.A. | Health Technology |
| Private companies | 3 |
|---|---|
| IQVIA | |
| Simon-Kucher & Partners, Inc. | |
Priothera SAS
Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The private company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020. | Health Technology |
- Stock Market
- Insiders
- Simone Seiter
